{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-005975","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.248247+00:00","generated_at":"2026-05-30T06:41:49.302865+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioCryst Q3: ORLADEYO revenue $116.3M (+35.7%); raises FY total revenue guide to $443-448M","bullets":["Q3 total revenue $117.1M (+35.1% yoy) led by ORLADEYO net revenue of $116.3M.","GAAP operating profit of $7.7M vs. loss of $11.9M in Q3 2023; non-GAAP op. profit $24.9M.","Net loss narrowed to $14.0M ($0.07 per share) from $36.1M ($0.19) a year ago.","FY 2024 ORLADEYO revenue guidance raised to $430-435M (top end of prior range); total revenue $443-448M.","Pipeline: BCX17725 for Netherton syndrome entered clinic; avoralstat for DME on track for 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-005975","json":"https://secwatch.observer/filing/0001171843-24-005975.json","markdown":"https://secwatch.observer/filing/0001171843-24-005975.md","text":"https://secwatch.observer/filing/0001171843-24-005975.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184324005975/0001171843-24-005975-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184324005975/f8k_110424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:41:49.302865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}